BI 690517 + Empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor
Phase 2
Indication: Chronic kidney disease
US FDA Fast Track Designation
This compound is under investigation, further information will be available soon.
Phase 2
Indication: Chronic kidney disease
US FDA Fast Track Designation
This compound is under investigation, further information will be available soon.